Consequences of the development of new antituberculous drugs for the treatment of tuberculosis.
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D004338:Drug Combinations; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin